| P2093 | author name string | Isaac O Donkor | |
| P2860 | cites work | Amelioration of retinal degeneration and proteolysis in acute ocular hypertensive rats by calpain inhibitor ((1S)-1-((((1S)-1-benzyl-3-cyclopropylamino-2,3-di-oxopropyl)amino)carbonyl)-3-methylbutyl)carbamic acid 5-methoxy-3-oxapentyl ester. | Q54592052 |
| | Novel dual inhibitors of calpain and lipid peroxidation with enhanced cellular activity. | Q55470694 |
| | Synthesis of a 24-Membered Cyclic Peptide-Biphenyl Hybrid | Q58035473 |
| | Isolation and structure elucidation of two new calpain inhibitors from Streptomyces griseus | Q71991558 |
| | A Ca(2+) switch aligns the active site of calpain | Q27638321 |
| | Development of calpain-specific inactivators by screening of positional scanning epoxide libraries | Q27643516 |
| | Cocrystal Structures of Primed Side-Extending α-Ketoamide Inhibitors Reveal Novel Calpain-Inhibitor Aromatic Interactions # | Q27651571 |
| | Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin | Q27652954 |
| | Calpains and muscular dystrophies | Q28144209 |
| | Benzoylalanine-derived ketoamides carrying vinylbenzyl amino residues: discovery of potent water-soluble calpain inhibitors with oral bioavailability | Q28207370 |
| | The novel calpain inhibitor SJA6017 improves functional outcome after delayed administration in a mouse model of diffuse brain injury | Q28207556 |
| | Proteases universally recognize beta strands in their active sites | Q28238770 |
| | Structure, activation, and biology of calpain | Q28241296 |
| | Determination of peptide substrate specificity for mu-calpain by a peptide library-based approach: the importance of primed side interactions | Q28276503 |
| | Molecular mode of action of a covalently inhibiting peptidomimetic on the human calpain protease core | Q28596594 |
| | Comprehensive behavioral phenotyping of calpastatin-knockout mice | Q30483897 |
| | Novel 6-hydroxy-3-morpholinones as cornea permeable calpain inhibitors | Q30884886 |
| | Exploration of orally available calpain inhibitors: peptidyl alpha-ketoamides containing an amphiphile at P3 site | Q30990832 |
| | Synthesis and calpain inhibitory activity of alpha-ketoamides with 2,3-methanoleucine stereoisomers at the P2 position | Q31585865 |
| | Exploration of cornea permeable calpain inhibitors as anticataract agents | Q33186330 |
| | Synthesis of a small library of diketopiperazines as potential inhibitors of calpain. | Q33215176 |
| | Identification of a novel calpain inhibitor using phage display | Q33217943 |
| | Design and synthesis of 4-aryl-4-oxobutanoic acid amides as calpain inhibitors | Q33388021 |
| | Evaluation of a novel calpain inhibitor as a treatment for cataract | Q33417055 |
| | Identification of 3-acetyl-2-aminoquinolin-4-one as a novel, nonpeptidic scaffold for specific calpain inhibitory activity | Q33439900 |
| | Neuroprotection with delayed calpain inhibition after transient forebrain ischemia | Q33839760 |
| | A survey of calpain inhibitors | Q34060656 |
| | Peptidyl alpha-ketoamides with nucleobases, methylpiperazine, and dimethylaminoalkyl substituents as calpain inhibitors | Q34194374 |
| | Investigation into the P3 binding domain of m-calpain using photoswitchable diazo- and triazene-dipeptide aldehydes: new anticataract agents | Q34627750 |
| | Calpains as potential anti-cancer targets | Q34793288 |
| | Calpains and disease | Q36156260 |
| | Calpain inhibition: a therapeutic strategy targeting multiple disease states. | Q36393620 |
| | Novel dual inhibitors of calpain and lipid peroxidation | Q44941185 |
| | Crystal structures of calpain-E64 and -leupeptin inhibitor complexes reveal mobile loops gating the active site | Q45112642 |
| | Reduction of myocardial infarction by calpain inhibitors A-705239 and A-705253 in isolated perfused rabbit hearts | Q45171362 |
| | Ritonavir does not inhibit calpain in vitro | Q45209533 |
| | Synthesis and evaluation of eight-membered cyclic pseudo-dipeptides | Q45209605 |
| | Human immunodeficiency virus (HIV)-induced neurotoxicity: roles for the NMDA receptor subtypes. | Q45420727 |
| | Molecular modeling, synthesis, and biological evaluation of macrocyclic calpain inhibitors. | Q46161964 |
| | Solid-phase combinatorial synthesis of peptide-biphenyl hybrids as calpain inhibitors | Q46208927 |
| | A new epicatechin gallate and calpain inhibitory activity from Orostachys japonicus | Q46269852 |
| | Calpain inhibition and insulin action in cultured human muscle cells | Q46464191 |
| | Synthesis and biological evaluation of chromone carboxamides as calpain inhibitors | Q46505388 |
| | Synthesis, biological evaluation and molecular modelling of N-heterocyclic dipeptide aldehydes as selective calpain inhibitors. | Q46525630 |
| | Chlortetracycline and demeclocycline inhibit calpains and protect mouse neurons against glutamate toxicity and cerebral ischemia | Q46642858 |
| | Novel cell-penetrating alpha-keto-amide calpain inhibitors as potential treatment for muscular dystrophy | Q46721993 |
| | Design and synthesis of 4-quinolinone 2-carboxamides as calpain inhibitors | Q46892708 |
| | Calpain inhibitor MDL-28170 reduces the functional and structural deterioration of corpus callosum following fluid percussion injury | Q48121937 |
| | Calpastatin levels affect calpain activation and calpain proteolytic activity in APP transgenic mouse model of Alzheimer's disease | Q48162315 |
| | Inhibition of calpain-mediated cell death by a novel peptide inhibitor | Q48427996 |
| | VE-cadherin-derived cell-penetrating peptide, pVEC, with carrier functions | Q48779585 |
| | A novel dual inhibitor of calpains and lipid peroxidation (BN82270) rescues the cochlea from sound trauma. | Q50457945 |
| | Implication of calpain in neuronal apoptosis. A possible regulation of Alzheimer's disease | Q36554860 |
| | Involvement of calpain activation in neurodegenerative processes. | Q36588397 |
| | The therapeutic potential of the calpain family: new aspects. | Q36601917 |
| | The calpains: modular designs and functional diversity | Q36672357 |
| | Calpains and their multiple roles in diabetes mellitus | Q36675894 |
| | Calpain activity in retinal degeneration. | Q36685247 |
| | Calpain-mediated regulation of platelet signaling pathways | Q36783478 |
| | Mechanistic role of calpains in postischemic neurodegeneration | Q37029897 |
| | The role of calcium-activated protease calpain in experimental retinal pathology | Q37113015 |
| | Calpain as a potential therapeutic target in Parkinson's disease | Q37232901 |
| | Calpain-mediated signaling mechanisms in neuronal injury and neurodegeneration | Q37237452 |
| | Calpain as a therapeutic target in traumatic brain injury | Q37686765 |
| | Calpains: attractive targets for the development of synthetic inhibitors | Q37694672 |
| | Regulation of calpain-2 in neurons: implications for synaptic plasticity | Q37798196 |
| | The role of calpain in diabetes-associated platelet hyperactivation. | Q37798968 |
| | Expanding members and roles of the calpain superfamily and their genetically modified animals | Q37804653 |
| | Evidence for calpain-mediated androgen receptor cleavage as a mechanism for androgen independence | Q40073673 |
| | A new cell-permeable calpain inhibitor. | Q40223788 |
| | Synthesis, calpain inhibitory activity, and cytotoxicity of P2-substituted proline and thiaproline peptidyl aldehydes and peptidyl alpha-ketoamides | Q40242934 |
| | Calpain inhibitors and antioxidants act synergistically to prevent cell necrosis: effects of the novel dual inhibitors (cysteine protease inhibitor and antioxidant) BN 82204 and its pro-drug BN 82270. | Q40245964 |
| | Exploration of orally available calpain inhibitors 2: peptidyl hemiacetal derivatives | Q40264619 |
| | Treatment of rats with calpain inhibitors prevents sepsis-induced muscle proteolysis independent of atrogin-1/MAFbx and MuRF1 expression | Q40321294 |
| | 1,2-Benzothiazine 1,1-dioxide alpha-ketoamide analogues as potent calpain I inhibitors | Q40580239 |
| | Calpastatin exon 1B-derived peptide, a selective inhibitor of calpain: enhancing cell permeability by conjugation with penetratin. | Q40652159 |
| | Calpain is involved in the HIV replication from the latently infected OM10.1 cells | Q40659344 |
| | Cellular uptake of an alpha-helical amphipathic model peptide with the potential to deliver polar compounds into the cell interior non-endocytically | Q40996709 |
| | HIV-1 Tat C-terminus is cleaved by calpain 1: implication for Tat-mediated neurotoxicity | Q41765004 |
| | Direct effect of human immunodeficiency virus protease inhibitors on neutrophil function and apoptosis via calpain inhibition | Q41829112 |
| | Synthesis and calpain inhibitory activity of peptidomimetic compounds with constrained amino acids at the P2 position | Q41846613 |
| | Structural basis for the potent calpain inhibitory activity of peptidyl alpha-ketoacids | Q41940642 |
| | A novel series of urea-based peptidomimetic calpain inhibitors. | Q42166244 |
| | Calpain inhibition by alpha-ketoamide and cyclic hemiacetal inhibitors revealed by X-ray crystallography. | Q42688028 |
| | Molecular modeling studies of peptide inhibitors highlight the importance of conformational prearrangement for inhibition of calpain | Q43054948 |
| | The novel calpain inhibitor A-705253 potently inhibits oligomeric beta-amyloid-induced dynamin 1 and tau cleavage in hippocampal neurons. | Q43213857 |
| | Synthesis and biological evaluation of novel piperidine carboxamide derived calpain inhibitors | Q43507699 |
| | Calpain inhibitor, SJA6017, reduces the rate of formation of selenite cataract in rats | Q43681124 |
| | Synthesis of a reported calpain inhibitor isolated from Streptomyces griseus. | Q43733834 |
| | 1,2-Benzothiazine 1,1-dioxide P(2)-P(3) peptide mimetic aldehyde calpain I inhibitors | Q43755661 |
| | Discovery of phenyl alanine derived ketoamides carrying benzoyl residues as novel calpain inhibitors | Q43981452 |
| | Ritonavir inhibition of calcium-activated neutral proteases | Q43984010 |
| | Exploration of peptidyl hydrazones as water-soluble calpain inhibitors | Q44011778 |
| | Structural determinants of the calpain inhibitory activity of calpastatin peptide B27-WT. | Q44261564 |
| | Structure-activity relationship study and drug profile of N-(4-fluorophenylsulfonyl)-L-valyl-L-leucinal (SJA6017) as a potent calpain inhibitor | Q44320330 |
| | Peptidyl aldehyde inhibitors of calpain incorporating P2-proline mimetics | Q44345391 |
| | Poly-arginine-fused calpastatin peptide, a living cell membrane-permeable and specific inhibitor for calpain | Q44563746 |
| | Calpain inhibitors, a treatment for Alzheimer's disease: position paper | Q44591036 |
| | Design, synthesis, molecular modeling studies, and calpain inhibitory activity of novel alpha-ketoamides incorporating polar residues at the P1'-position | Q44706434 |
| | Studies on aromatic compounds: inhibition of calpain I by biphenyl derivatives and peptide-biphenyl hybrids. | Q44882624 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | scientific literature | Q12042160 |
| P304 | page(s) | 601-636 | |
| P577 | publication date | 2011-03-24 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | Calpain inhibitors: a survey of compounds reported in the patent and scientific literature | |
| P478 | volume | 21 | |